Podcasts

OUTSPOKEN ONCOLOGY

Episode 52: Advances in Prostate Cancer With Neeraj Agarwal

05/03/2022

Neeraj Agarwal, MD, discusses management decisions for patients with advanced or metastatic prostate cancer, including weariness in using ADT for many patients with comorbidities and how clinicians are currently weighing existing regimens.

Neeraj Agarwal, MD, discusses...

05/03/2022

Journal of Clinical Pathways

OUTSPOKEN ONCOLOGY

Episode 51: Interventional Pharmacoeconomics With Daniel Goldstein

05/03/2022

Daniel Goldstein, MD, Rabin Medical Center (Israel), discusses the ability of interventional pharmacoeconomics to lower drug costs and increase access around the world, as well as the dilemma physicians face for treating patients with a...

Daniel Goldstein, MD, Rabin...

05/03/2022

Journal of Clinical Pathways

OUTSPOKEN ONCOLOGY

Episode 50: Evidence-Based Medicine: What Does it Really Mean?

05/03/2022

John Mandrola, MD, explains how all medical evidence is flawed and a critical mistake HCPs can make with overgeneralizing the results of clinical trials.

John Mandrola, MD, explains how...

05/03/2022

Journal of Clinical Pathways

OUTSPOKEN ONCOLOGY

Episode 49: Addressing Drug Prices With Stacie Dusetzina

05/03/2022

Stacie Dusetzina, PhD, Vanderbilt University School of Medicine, discusses the "desensitization" of society to cancer prescription drug costs and solutions proposed by politicians for inflated Medicare Part D spending, among other topics.

Stacie Dusetzina, PhD,...

05/03/2022

Journal of Clinical Pathways

OUTSPOKEN ONCOLOGY

Episode 48: Overcoming Challenges of Clinical Research in the Community

05/03/2022

Michael Thompson, MD, PhD, Advocate Aurora Health Care, discusses social determinants of health, eligibility criteria, and other barriers to clinical trial enrollment in the community setting, as well as the importance of real-world evidence...

Michael Thompson, MD, PhD,...

05/03/2022

Journal of Clinical Pathways

OUTSPOKEN ONCOLOGY

Episode 47: The Global Oncology Agenda With Gilberto Lopes

05/03/2022

Gilberto Lopes, MD, discusses the intersection of globalization and localization of cancer care and measuring success in a global oncology program, among other topics.

Gilberto Lopes, MD, discusses...

05/03/2022

Journal of Clinical Pathways

OUTSPOKEN ONCOLOGY

Episode 45: Simplifying Biosimilars With Gary Lyman

05/03/2022

Gary Lyman, MD, MPH, details why it may take 8-12 years to prove that biosimilars should be trusted in everyday clinical practice and touches on issues of granting extrapolation.

Gary Lyman, MD, MPH, details why...

05/03/2022

Journal of Clinical Pathways

OUTSPOKEN ONCOLOGY

Episode 44: Payer's Approach to Social Determinants of Health

05/03/2022

Andrew Renda, MD, associate vice president of population health at Humana, discusses ways in which Humana designs supplemental benefits for social needs as well as addresses social determinants of health to close clinical gaps in care.

Andrew Renda, MD, associate vice...

05/03/2022

Journal of Clinical Pathways

OUTSPOKEN ONCOLOGY

Episode 43: Chasing My Cure With David Fajgenbaum

05/03/2022

David Fajgenbaum, MD, MBA, MSc, survivor of Castleman disease and author of "Chasing My Cure," discusses treating his own disease through experimental self-administered therapies and involvement in developing the first NCCN guidelines and...

David Fajgenbaum, MD, MBA, MSc,...

05/03/2022

Journal of Clinical Pathways

OUTSPOKEN ONCOLOGY

Episode 42: Updates and Controversies in CML With Matt Kalaycio

05/03/2022

Matt Kalaycio, MD, Cleveland Clinic, simplifies initial therapy and monitoring decisions for CML, financial implications for patients treated with TKIs, and treatment choices dictated by payers for patients with specific characteristics.

Matt Kalaycio, MD, Cleveland...

05/03/2022

Journal of Clinical Pathways